Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors

[1]  S. Eschrich,et al.  Tumour radiosensitivity is associated with immune activation in solid tumours. , 2017, European journal of cancer.

[2]  M. Fernö,et al.  Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Ian Krop,et al.  Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Esserman,et al.  Precision surgery and avoiding over-treatment. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  N. Harbeck,et al.  Breast cancer , 2017, The Lancet.

[6]  S. Eschrich,et al.  Integrating Biological Covariates into Gene Expression-Based Predictors of Radiation Sensitivity , 2017, International journal of genomics.

[7]  Jacob G. Scott,et al.  A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. , 2017, The Lancet. Oncology.

[8]  Anushya Muruganujan,et al.  PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements , 2016, Nucleic Acids Res..

[9]  L. Holmberg,et al.  No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT. , 2016, European journal of cancer.

[10]  R. Bast,et al.  Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Coles,et al.  It's PRIMETIME. Postoperative Avoidance of Radiotherapy: Biomarker Selection of Women at Very Low Risk of Local Recurrence. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

[12]  Wei Zhu,et al.  Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy , 2016, Nature Communications.

[13]  O. Stål,et al.  Met and its ligand HGF are associated with clinical outcome in breast cancer , 2016, Oncotarget.

[14]  S. Barillé-Nion,et al.  Survivin contributes to DNA repair by homologous recombination in breast cancer cells , 2015, Breast Cancer Research and Treatment.

[15]  M. J. van de Vijver,et al.  Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer. , 2015, International journal of radiation oncology, biology, physics.

[16]  Felix Y. Feng,et al.  Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer , 2015, Clinical Cancer Research.

[17]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[18]  Donald Geman,et al.  switchBox: an R package for k-Top Scoring Pairs classifier development , 2015, Bioinform..

[19]  Å. Borg,et al.  High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer , 2014, Breast Cancer Research and Treatment.

[20]  A. Frigessi,et al.  Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort , 2014, Clinical Cancer Research.

[21]  Sean Ferree,et al.  Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens , 2014, BMC Cancer.

[22]  Donald Geman,et al.  Rank discriminants for predicting phenotypes from RNA expression , 2014, 1401.1490.

[23]  J. Bergh,et al.  Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis , 2013, Genome Biology.

[24]  Lu Tian,et al.  A Simple Method for Detecting Interactions between a Treatment and a Large Number of Covariates , 2012, 1212.2995.

[25]  Yudi Pawitan,et al.  Validation of a Radiosensitivity Molecular Signature in Breast Cancer , 2012, Clinical Cancer Research.

[26]  Emmanuel Barillot,et al.  Search for a Gene Expression Signature of Breast Cancer Local Recurrence in Young Women , 2012, Clinical Cancer Research.

[27]  Wei Shi,et al.  BeadArray Expression Analysis Using Bioconductor , 2011, PLoS Comput. Biol..

[28]  Early Breast Canc Trialists Collab.  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials , 2011 .

[29]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[30]  M. Ringnér,et al.  Prediction of Stage, Grade, and Survival in Bladder Cancer Using Genome-wide Expression Data: A Validation Study , 2010, Clinical Cancer Research.

[31]  Carsten Peterson,et al.  Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy , 2008, Breast Cancer Research.

[32]  F. B. Sørensen,et al.  Impact of BCL2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c , 2008, Acta oncologica.

[33]  Emmanuel Chamorey,et al.  HIF‐1α and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome , 2007 .

[34]  Howard Y. Chang,et al.  Predicting a local recurrence after breast-conserving therapy by gene expression profiling , 2006, Breast Cancer Research.

[35]  M. J. van de Vijver,et al.  Gene Expression Profiles of Primary Breast Carcinomas from Patients at High Risk for Local Recurrence after Breast-Conserving Therapy , 2006, Clinical Cancer Research.

[36]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[37]  Carsten O. Peterson,et al.  Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. , 2001, Cancer research.

[38]  K. Roberg,et al.  Nuclear expression of WRAP53β is associated with a positive response to radiotherapy and improved overall survival in patients with head and neck squamous cell carcinoma. , 2015, Oral oncology.

[39]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[40]  Emmanuel Chamorey,et al.  HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. , 2007, International journal of cancer.